Scotiabank Starts ARS Pharmaceuticals Inc (SPRY) at Sector Outperform

Scotiabank analyst Louise Chen initiates coverage on ARS Pharmaceuticals Inc (NASDAQ: SPRY) with a Sector Outperform rating and a price target of $30.00.

The analyst comments "We have initiated coverage on the common shares of ARS Pharmaceuticals, Inc. (SPRY) with a Sector Outperform rating and a one-year target price of $30.00 per share. We believe it’s time to take a look at SPRY ahead of tailwinds that could drive robust uptake of its newly launched neffy, a nasal spray alternative to epinephrine injections for severe allergic reactions. The setup is good, in our view, with a product that addresses unmet needs, an experienced management team to launch it, and a price that is more affordable than generic epinephrine injections. We do not believe the potential for billions in sales is reflected in SPRY’s valuation."

For an analyst ratings summary and ratings history on ARS Pharmaceuticals Inc click here. For more ratings news on ARS Pharmaceuticals Inc click here.

Shares of ARS Pharmaceuticals Inc closed at $10.79 yesterday.

You May Also Be Interested In